Enovix Option Alert: Aug 15 $10 Calls Sweep (87) near the Ask: 6950 vs 1987 OI

Enovix Option Alert: Aug 15 $10 Calls Sweep (87) near the Ask: 6950 @ $0.76 vs 1987 OI; Ref=$7.97

Enovix (NASDAQ:ENVX) Bolsa

ENOVIX CORP

Enovix

Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.

Equities

News

Markets

CVNA

ENVX

GRAB

PLTR

TSLA

Tesla, Palantir, Carvana, Enovix, Grab Holdings: descubre qué movió el mercado y qué esperar de estas acciones clave.

Palantir, Carvana, Enovix, Grab, Tesla: 5 acciones que están en el radar de los inversores

Enovix Corp

Needham analyst Mike Cikos reiterates Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) with a Buy and maintains $24 price target.

Price Target

Reiteration

Analyst Ratings

CLBT

Needham Reiterates Buy on Cellebrite DI, Maintains $24 Price Target

Fury Gold Mines Limited (NYSE:<a href="https://www.benzinga.com/stock/FURY#NYSE">FURY</a>) ("Fury" or the "Company") announces that the proposed private placement offering announced June 5, 2025 has been increased from C$2,500,000 to C$3,080,000. Fury now intends to privately place with a small group of accredited and institutional investors in Canada a total of 4,000,000 flow-through common shares (the "Shares") of the Company, at a price of C$0.77 per Share for total gross proceeds of C$3,080,000 (the "Offering"). This offering figure could increase by up to approximately 15.4% if a strategic investor elects to exercise its pre-emptive participation rights disclosed in a <a href="https://www.globenewswire.com/Tracker?data=HQaYc8Cgq_iu2dRsUPGUu4P8s3eHB2eh9WbW-ZLoEWjXoCqjvRLyTfYk3hp6kqzAmBb84_tbBVoR_n5MFK0Ixq9Z6MdXWXYjmhnHy6AtbvrgY_wLYJ1ItwqiqvhkOwikomCI1oUBmQMZQ53iXZrkOtyfCPzsDPY_b__Zik8XVFI=">May 27, 2025 news release</a>.
The Offering is expected to close on or about June 19, 2025 (the "Closing Date"), subject to execution of subscription agreements and customary closing conditions, including receipt of all necessary approvals, including the approval of the Toronto Stock Exchange ("TSX") and the NYSE American LLC. Other previously announced terms and conditions remain the same.

FURY

Fury Gold Mines Increases Proposed Private Placement Offering From C$2.50M To C$3.08M

G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) is looking for Q2 Adj EPS of $0.02-$0.12 vs $0.48 analyst estimate. Q2 Revenue expected to be more than $570.00M vs $621.00M Est

Guidance

GIII

G-III Apparel Group Sees Q2 EPS $0.02-$0.12; Q2  Revenue Expected To Be Approximately $570.00M vs $621.00M Est

PRPH

ProPhase Labs Forms Clinical Science Advisory Board To Support Clinical Adoption And Commercialization Of Breakthrough BE-Smart Molecular Test For Esophageal Disease

D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) with a Buy and maintains $19 price target.

RCEL

D. Boral Capital Maintains Buy on AVITA Medical, Maintains $19 Price Target

Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) (the "Company" or "Sandisk") announced today the pricing of a secondary public offering (the "Offering") of 18,534,581 shares of its common stock (the "SNDK Shares") currently owned by Western Digital Corporation, the Company's former parent ("WDC"). The size of the offering reflects an increase from the 17,000,000 shares of common stock originally proposed to be sold. The SNDK Shares will be offered at a public offering price of $38.50 per share. Sandisk is not selling any shares of common stock and will not receive any proceeds from the sale of the SNDK Shares in the Offering or from the debt-for-equity exchange.

SNDK

Sandisk Announces Pricing For Expanded Secondary Offering; WDC to Sell 18.5M Shares, Priced at $38.50/Shr

Needham analyst Tom Nikic maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Buy and lowers the price target from $366 to $317.

LULU

Needham Maintains Buy on Lululemon Athletica, Lowers Price Target to $317

Manchester United (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.33) by 87.88 percent. This is a 87.1 percent increase over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $202.03 million which missed the analyst consensus estimate of $202.47 million by 0.22 percent. This is a 16.53 percent increase over sales of $173.37 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

MANU

Manchester United Q3 Adj. EPS $(0.04) Beats $(0.33) Estimate, Sales $202.03M Miss $202.47M Estimate

G-III Apparel Anticipates Unmitigated Cost Of Tariffs On Goods Imported Into The United States Will Result In Additional Expense Of $135M, Which Will Primarily Be Weighted To The Second Half Of The Year

<a href="https://www.globenewswire.com/Tracker?data=n4VAc1wDtm5Gx7yfSA9G9Bdm2S_5VbQKkJDwPg3B940asDE5ZukU5_AOibtKC3kemI6XkVzqXtwCjRwSJvfq1cpQeANnCCU7jEhQPnli8rQ=">BioCryst Pharmaceuticals, Inc. </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO&#xAE; (berotralstat) has been approved for the routine prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older. This reimbursement approval in the Netherlands marks national reimbursement for ORLADEYO across all major European countries, providing HAE patients with access to the first oral, once-daily preventive therapy.

BCRX

Netherlands Approves BioCryst Pharma's ORLADEYO For Hereditary Angioedema Prevention, Expanding National Access Across Europe

G-III Apparel Has Withdrawn Its Net Income, Non-GAAP Net Income And Adjusted EBITDA Guidance For FY26 Due To Uncertainty Around Tariffs And Related Macroeconomic Conditions

Strategy&#x2122; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) today announced the pricing of its initial public offering on June 5, 2025 of 11,764,700 shares of 10.00% Series A Perpetual Stride Preferred Stock (the "STRD Stock"), at a public offering price of $85.00 per share. The issuance and sale of the STRD Stock are scheduled to settle on June 10, 2025, subject to customary closing conditions.
Strategy estimates that the net proceeds to it from the offering will be approximately $979.7 million, after deducting the underwriting discounts and commissions and Strategy's estimated offering expenses. Strategy intends to use the net proceeds from the offering for general corporate purposes, including the acquisition of bitcoin and for working capital.

IPOs

MSTR

Strategy Prices IPO Of 11.8M Shares Of 10.00% Series A Perpetual Stride Preferred Stock At Public Offering Price Of $85.00/Shr

G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) affirms FY2026 sales outlook from $3.14 billion to $3.14 billion vs $3.12 billion estimate.

G-III Apparel Group Affirms FY2026 Sales Guidance of $3.14B vs $3.12B Est

Needham analyst Scott Berg reiterates Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) with a Buy and maintains $50 price target.

BRZE

Needham Reiterates Buy on Braze, Maintains $50 Price Target

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine –
– VERITAC-2 data support vepdegestrant as a potential treatment option in patients with ESR1m ER+/HER2- advanced or metastatic breast cancer –
NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), for vepdegestrant for the treatment of patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. This submission is based on results from VERITAC-2 (NCT05654623), a global, randomized Phase 3 trial evaluating vepdegestrant versus fulvestrant.

ARVN

Arvinas Submits NDA To FDA With Partner Pfizer For Vepdegestrant For Treatment Of Patients With ER+/HER2- ESR1-Mutated Advanced Or Metastatic Breast Cancer Previously Treated With Endocrine-Based Therapy

Needham analyst Scott Berg reiterates ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) with a Buy and maintains $140 price target.

TTAN

Needham Reiterates Buy on ServiceTitan, Maintains $140 Price Target

G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.12 by 58.33 percent. This is a 58.33 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $583.61 million which beat the analyst consensus estimate of $580.37 million by 0.56 percent. This is a 4.29 percent decrease over sales of $609.75 million the same period last year.

G-III Apparel Group Q1 Adj. EPS $0.19 Beats $0.12 Estimate, Sales $583.61M Beat $580.37M Estimate

U.S. Health Secretary Robert F. Kennedy Jr. has championed &#8220;medical freedom&#8221; while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health experts call a dichotomy in his approach to healthcare policy.
What Happened: Kennedy announced last week that the Centers for Disease Control and Prevention would remove COVID-19 vaccines from <a href="https://www.benzinga.com/news/25/05/45661031/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-children">recommended </a>immunization schedules for healthy children and pregnant women.
The decision bypassed traditional advisory committee processes and shifted coverage from routine recommendations to shared clinical decision-making between doctors and patients.
&#8220;Regarding the vaccines, HHS is restoring the doctor-patient relationship,&#8221; HHS spokesperson Andrew Nixon said in a <a href="https://abcnews.go.com/Health/rfk-jr-promoted-freedom-choice-limiting-vaccines-food/story?id=122526364">statement</a> to ABC News. &#8220;We are encouraging those groups to consult with their health care provider to help them make an informed decision.&#8221;
Kennedy has also pushed to ban Supplemental Nutrition Assistance Program recipients from purchasing candy and soda with food stamps. Ten state governors have submitted waivers to the Agriculture Department requesting permission for such restrictions, according to Kennedy&#8217;s statements at a Make America Healthy Again event in May.
The Food and Drug Administration began <a href="https://www.benzinga.com/government/regulations/25/05/45399804/robert-kennedy-jr-cheers-fda-plan-to-ban-fluoride-supplements-for-children-calls-move-long-overdue">removing fluoride supplements for children </a>from the market, earning Kennedy&#8217;s praise as &#8220;long overdue.&#8221; The agency cited a lack of FDA approval and evidence that these products alter gut microbiomes.
Kennedy&#8217;s broader MAHA initiative has influenced restaurant chains to eliminate seed oils. Biglari Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BH#NYSE">BH</a>) subsidiary Steak &#8216;n Shake switched to beef tallow for French fries, while Sweetgreen Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>), Bloomin&#8217; Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>), and Restaurant Brands International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) have initiated similar transitions.
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/45809455/tesla-stock-climbed-nearly-5-in-friday-pre-market-whats-going-on">Tesla Stock Climbed Nearly 5% In Friday Pre-Market: What&#8217;s Going On?</a>
Why It Matters: Critics argue Kennedy&#8217;s policies contradict his &#8220;medical freedom&#8221; messaging by limiting choices. Removing COVID vaccines from CDC schedules restricts access while claiming to promote freedom.
&#8220;If you restrict access, you necessarily restrict choice,&#8221; Dr. Matthew Ferrari of Pennsylvania State University told ABC News. Public health experts warn Kennedy&#8217;s approach individualizes community health decisions. &#8220;We&#8217;re losing a lot of that underpinning, which has led to a lot of the gains in public health,&#8221; Dr. Craig Spencer of Brown University told ABC News.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45809443/larry-summers-identifies-3-key-reasons-for-rising-us-debt-but-doesnt-think-trumps-big-beautiful-bill-is-the-medicine-the-country-needs">Larry Summers Identifies 3 Key Reasons For Rising US Debt, But Doesn&#8217;t Think Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Is The Medicine The Country Needs</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Health Care

BLMN

MRNA

NVAX

RFK Jr. Champions 'Medical Freedom' While Curtailing Access, Say Public Health Experts

Scammers are hijacking tariff headlines to trick online shoppers into paying for packages that never arrive, the Better Business Bureau warned this week.
What Happened: BBB spokesperson Melanie McGovern urged consumers to vet unfamiliar retailers, scrutinize delivery windows and read return policies before clicking "buy." In a statement <a href="https://www.usatoday.com/story/money/2025/06/05/package-delays-tariffs-scam/84047764007/">shared</a> with USA Today, McGovern said, &#8220;Scammers rely on consumer confusion, especially when it comes to topics in the news, so doing a little bit extra to make sure the website is legitimate, and that all costs are upfront, can save headaches down the road.&#8221;
Victims typically click a sponsored ad, buy from a slick-looking site and then receive only canned emails urging patience, the BBB says. Weeks later, the seller claims the package is stuck in customs because of new tariffs or demands extra cash to "release" it. Some fraudsters even send tracking numbers that show delivery to the wrong state. A Wisconsin shopper told BBB Scam Tracker she got silence after asking for a refund on shoes delayed "due to tariffs."
U.S. customers rarely owe tariffs after checkout, so any post-purchase demand for customs fees is a red flag, the bureau added. The U.S. Postal Inspection Service urges shoppers to ignore texts that claim package delays and request link clicks.
See also: <a href="https://www.benzinga.com/markets/tech/25/06/45809827/sam-altman-says-ai-can-replace-interns-but-gen-z-is-already-treating-it-like-a-work-buddy">Sam Altman Says AI Can Replace Interns, But Gen Z Is Already Treating It Like A Work Buddy</a>
Why It Matters: To stay safe, experts recommend researching sellers beyond sponsored ads, reading independent reviews and looking for misspellings or odd URLs. Use a credit card, never a debit card or payment app and walk away if asked to pay more after checkout.
The BBB also urges victims to file disputes with their card issuer and report cases to its Scam Tracker, which logged dozens of complaints describing the same "customs hold" ploy. Similar tactics appear in broader package-redirection fraud that manipulates tracking data to block refunds.
Fortalice Solutions CEO Theresa Payton recently called tariff confusion "<a href="https://www.benzinga.com/personal-finance/25/05/45673001/tariff-confusion-creates-the-perfect-storm-for-cybercriminals-consumer-scams-on-the-rise">the perfect storm</a>" for cybercriminals. Similarly, James Lee, the president of the Identity Theft Resource Center, reiterated that it isn&#8217;t unusual for scammers to use a government action as the basis of a scam.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/markets/tech/25/06/45808672/nvidia-denies-report-of-re-entering-chinese-market-with-custom-ai-chip-despite-us-restrictions-we-are-still-evaluating">Nvidia Denies Report Of Re-Entering Chinese Market With Custom AI Chip, Despite US Restrictions: &#8216;We Are Still Evaluating&#8230;&#8217;</a>

Tech

Scammers Exploit Tariff Confusion To Dupe Online Shoppers Into Paying For Packages That Never Arrive, BBB Warns — Here's How To Spot The Red Flags

Needham analyst Scott Berg reiterates Docusign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) from Hold to Hold.

Comments

Enovix

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL